Taken together, these results strongly suggest that PPA2 relies on K176 succinylation to inhibit HIF-1α-mediated CRC metastasis, highlighting the potential of PPA2 K176 succinylation level as a valuable biomarker for predicting mCRC risk and guiding treatment strategies. Here, PPA2 is linked to colorectal carcinoma.